Jan 13, 2022 5:00 pm EST Recently Published Data Confirm DecisionDx®-SCC as a Significant and Independent Risk-Stratification Tool in Patients with Squamous Cell Carcinoma and One or More Risk Factors
Jan 12, 2022 7:00 am EST Data Published in Ocular Oncology and Pathology Demonstrates Highly Accurate Performance of DecisionDx®-UMSeq for Patients with Uveal Melanoma
Jan 10, 2022 7:00 am EST Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2021 Results
Nov 24, 2021 7:00 am EST Castle Biosciences Presents Data Reinforcing the Clinical Utility of Its DecisionDx® Dermatologic Portfolio
Nov 19, 2021 7:00 am EST Data Demonstrating DecisionDx®-Melanoma Was a Significant, Independent Predictor of Metastatic Recurrence in Stage I-III Cutaneous Melanoma Published in Future Oncology
